Skip to main content
Pay Bill Portals

Signatera Publications

Bladder Cancer | Breast Cancer | Colorectal Cancer | Other GastroIntestinal Malignancies | Genitourinary (GU) Cancer | Head and Neck Cancer | Lung Cancer
Melanoma | Merkel Cell Carcinoma | Multiple Myeloma | Ovarian Cancer | Pancancer | Pancreatic Cancer | Sarcoma

Bladder Cancer

  1. Lindskrog SV, Birkenkamp-Demtroder K, Nordentoft I, et al. Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clinical Cancer Research. 2023; Oct 2. doi: 10.1158/1078-0432.CCR-23-1860
  2. Powles T, Assaf ZA, Degaonkar V, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. 2023; doi: 10.1016/j.eururo.2023.06.007
  3. Szabados B, Kockx M, Assaf ZA, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. European Urology. 2022; 82, 212-222
  4. Powles T, Assaf ZA, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021; 82, 212-222
  5. Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology. 2019: 37(18):1547-1557

Breast Cancer

  1. Shaw J, et al. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer. JCO Precis Oncol. 2024;8:e2300456.
  2. Magbanua MJM, Swigart LB, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-1102.
  3. Gruber JJ, Afghani A, Timss K, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer. 2022; https://doi.org/10.1038/s43018-022-00439-1
  4. Cailleux F, Agostinetto E, Lambertini M, et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO-Precision Oncology. 2022; 6: e2200148.
  5. Azzi G, Krinshpun S, Tin A, et al. Treatment response monitoring using a tumor-informed circulating tumor DNA test in an advanced triple negative breast cancer patient: A case report. Case Reports in Oncology. 2022;15:473-479.
  6. Magbanua MJM, Wen L, Wolf DM, et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021;7(32):1-8.
  7. Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival. Annals of Oncology. 2021;32(2):229-239.
  8. Coombes C, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research. 2019;25(14):4255-4263.

Colorectal Cancer

  1. Dhiman A, Kothary V, Witmer HD, et al. Role of Tumor-informed Personalized ctDNA Assay in Informing Recurrence in Patients with Peritoneal Metastases from Colorectal and High-grade Appendix Cancer Undergoing Curative Intent Surgery. Annals of Surgery. 2023 Mar 30. doi: 10.1097/SLA.0000000000005856. Online ahead of print.
  2. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nature Medicine. 2023;29(1):127-134.
  3. Alden SL, Dhani H, Palsuledesai C, et al. Post-operative ctDNA monitoring in stage I colon cancer: A case report. Frontiers in Oncology. 2022;12:1074786.
  4. Kasi PM, Budde G, Krainock M, et al. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 2022;10:e003312.
  5. Miyo M, Kato T, Nakamura Y, et al. DENEB: Development of a new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy. Cancer Science. 2022; 113:1531-1534.
  6. Weinberg BA, Winslow ER, Bayasi M, et al. Early detection of circulating tumor DNA post-operatively enables discovery of resectable metastatic disease in a patient with colon cancer. Case reports in Oncology. 2021;14:1748–1753.
  7. Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2021; 21-2404.
  8. Kasi PM, Sawyer S, Guilford J, et al. BESPOKE study protocol: A multicenter, prospective observational study to evaluate the impact of circulating tumor DNA guided therapy on patients with colorectal cancer. BMJ Open. 2021;11(9):e047831.
  9. Loupakis F, Sharma S, Derouazi M, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in colorectal cancer patients undergoing resection of metastases. JCO-Precision Oncology. 2021; 5:1166-1177.
  10. Schneider CJ, Krainock M, Malashevich AK, et al. ctDNA clearance and radiographic resolution of disease in response to dual checkpoint inhibition in metastatic microsatellite stable colorectal cancer with a high tumor mutation burden. Case reports in Oncology. 2021;14:849–853.
  11. Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science. 2021;112:2915–2920.
  12. Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stage I to III Colorectal Cancer. JAMA Oncology. 2019;5(8):1124-1131.

Other GastroIntestinal Malignancies (Esophageal, Anal Squamous Cell)

  1. Bhutiani M, Helmink BA, Zeineddine M, et al. Utility of Circulating tumor DNA in Appendiceal Tumors. Journal of Gastrointestinal Surgery. 2023; doi: 10.1007/s11605-023-05825-3
  2. Singh H, Klempner SJ, Melnitchouk N, et al. Highly sensitive circulating tumor DNA assay aids clinical management of radiographically occult isolated peritoneal metastases in patients with GI cancer. JCO-Precision Oncology. 2023; 7:e2200572.
  3. Azzi G, Tavallai M, Aushev VA, et al. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. The Oncologist. 2023; 28(3):220-229.
  4. Huffman BM, Aushev VN, Budde GL, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO-Precision Oncology. 2022; 6:e2200420.
  5. Ococks E, Sharma S, Ng AWT, et al. Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection. Gastroenterology. 2021; 161(5):1705-1708.e2.
  6. Einstein DJ, Liang N, Malhotra M, et al. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer with a Personalized Circulating Tumor DNA Assay. JCO-Precision Oncology. 2020;4:239-243.
  7. Zhang S, Brazel D, Kumar P, et al. Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. Gastrointestinal Oncology. 2021; doi: 10.21037/jgo-21-484

Genitourinary (GU) Cancer

  1. Jang A, Lanka SM, Jaeger EB, et al. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies. JCO Precis Oncol 2023;7:e2300131.

Head and Neck Cancer

  1. Oliva M, Chepeha D, Araujo D, et al. Antitumor Immune Effects of Pre-operative Sitravatinib and Nivolumab Lead to Major Clinical and Pathological Responses in Oral Cavity Cancer: The SNOW Window of Opportunity Study. Journal for ImmunoTherapy of Cancer. 2021;9(10), e003476.

Lung Cancer

  1. Youjin Oh, et al. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Thorac Cancer. 2024;1–8.
  2. Aaron C. Tan, et al. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer. Cancer. 2024,1-8.
  3. Travis K. Martin, et al. Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 2024.
  4. Lebow E, Shaverdian N, Eichholz JE, et al. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. Front. Oncol. 2023,13:1253629.
  5. Cascone T, Kar G, Spicer JD, et al. Neoadjuvant Durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: The Phase 2 NeoCOAST platform trial. Cancer Discov. 2023, https://doi.org/10.1158/2159-8290.CD-23-0436.
  6. Abbosh C, Birkbak N, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017,545:446–451.

Melanoma

  1. Rachel A. Fischer, et al. US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma. Critical Reviews in Oncology / Hematology. 196 (2024) 104289.
  2. Brunsgaard EK, Bowles TL, Asare EA, et al. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma patients. Melanoma Res. 2023;33(3):184-191.
  3. Eroglu Z, Krinshpun S, Kalashnikova E, et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129(11):1723-1734.
  4. Khaddour K, Zhou A, Butt OH, et al. Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. Front. Oncol. 2022;12: 978996.

Merkel Cell Carcinoma

  1. Park S J, Kannan A, Harris JP NH, et al. Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma. JAAD Case Report.

    doi: https://doi.org/10.1016/j.jaad.2022.03.020.

  2. Yeakel J, Kannan A, Rattigan NH, et al. Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory merkel cell carcinoma patient. JAAD Case Report.

    doi: https://doi.org/10.1016/j.jdcr.2021.10.025.

Multiple Myeloma

  1. Dhakal B, Sharma S, Balcioglu M et al. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Front. in Oncol. 2022; 12:786451.

Ovarian Cancer

  1. J.Y. Hou, J.S. Chapman, E. Kalashnikova et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology. 2022.

Pancancer

  1. Cohen S, Liu MC, Aleshin A. Practical recommendations for using ctDNA in clinical decision making. Nature. 2023; 619:259-268.
  2. Kasi PM, Chakrabarti S, Sawyer S, et al. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. BMJ Open. 2022;12:e060342.
  3. Cohen SA, Kasi A, Hook N, et al. The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant. Case Reports in Obstetrics and Gynecology. 2022:9412201.
  4. Kasi P, Fehringer G, Taniguchi H, et al. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO-PO. 2022;6:e2100181.
  5. Yang CSY, Lien SC, Wang BX, et al. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun. 2021;12:5137.
  6. Henriksen TV, Reinert T, Christensen T, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients - implications for studies of circulating tumor DNA. Molecular Oncology. 2020;14:1670-1679.
  7. Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020.1:873-881.

Pancreatic Cancer

  1. Abdelrahim M, Esmail A, Xu J, et al. Early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma using circulating tumor DNA. J Surg Res. 2021; 4(4):602-615.

Sarcoma

  1. Zhou M, Bui N, Rathore R, et al. Feasibility of longitudinal ctDNA assessments in patients with uterine and extra-uterine leiomyosarcoma. Cancers. 2023; 15, 157.